BRPI0406800A - Peptìdio dimerizado - Google Patents

Peptìdio dimerizado

Info

Publication number
BRPI0406800A
BRPI0406800A BR0406800-9A BRPI0406800A BRPI0406800A BR PI0406800 A BRPI0406800 A BR PI0406800A BR PI0406800 A BRPI0406800 A BR PI0406800A BR PI0406800 A BRPI0406800 A BR PI0406800A
Authority
BR
Brazil
Prior art keywords
peptide
tumor antigen
dimerized peptide
antigen peptide
dimerized
Prior art date
Application number
BR0406800-9A
Other languages
English (en)
Inventor
Haruo Sugiyama
Hideo Takasu
Fumio Samizo
Original Assignee
Haruo Sugiyama
Chugai Pharmaceutical Co Ltd
Sumitomo Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haruo Sugiyama, Chugai Pharmaceutical Co Ltd, Sumitomo Pharma filed Critical Haruo Sugiyama
Publication of BRPI0406800A publication Critical patent/BRPI0406800A/pt
Publication of BRPI0406800A8 publication Critical patent/BRPI0406800A8/pt
Publication of BRPI0406800B1 publication Critical patent/BRPI0406800B1/pt
Publication of BRPI0406800B8 publication Critical patent/BRPI0406800B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"PEPTìDIO DIMERIZADO". A presente invenção refere-se a um novo peptídio antígeno de tumor e a vacina para câncer do mesmo, de modo específico um dímero de peptídio, no qual dois monómeros de peptídio que consistem em 7 a 30 aminoácidos que incluem, pelo menos um resíduo de cisteína e sendo capazes de produzir um peptídio antígeno de tumor estão ligados um com o outro através de uma ligação de dissulfeto.
BRPI0406800A 2003-01-15 2004-01-15 "dímero de peptídeo, composição farmacêutica contendo o mesmo e seu uso BRPI0406800B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003007122 2003-01-15
JP2003-007122 2003-01-15
PCT/JP2004/000254 WO2004063217A1 (ja) 2003-01-15 2004-01-15 二量体化ペプチド

Publications (4)

Publication Number Publication Date
BRPI0406800A true BRPI0406800A (pt) 2006-01-17
BRPI0406800A8 BRPI0406800A8 (pt) 2016-11-01
BRPI0406800B1 BRPI0406800B1 (pt) 2020-08-11
BRPI0406800B8 BRPI0406800B8 (pt) 2021-05-25

Family

ID=32709100

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0406800A BRPI0406800B8 (pt) 2003-01-15 2004-01-15 "dímero de peptídeo, composição farmacêutica contendo o mesmo e seu uso

Country Status (13)

Country Link
US (2) US20060217297A1 (pt)
EP (2) EP2154145B1 (pt)
JP (2) JP4498274B2 (pt)
KR (2) KR101399678B1 (pt)
CN (2) CN1756763B (pt)
AT (1) ATE444969T1 (pt)
AU (1) AU2004204031B2 (pt)
BR (1) BRPI0406800B8 (pt)
CA (1) CA2513701C (pt)
DE (1) DE602004023476D1 (pt)
ES (1) ES2332590T3 (pt)
HK (2) HK1081975A1 (pt)
WO (1) WO2004063217A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4422903B2 (ja) * 1998-07-31 2010-03-03 株式会社癌免疫研究所 癌抑制遺伝子ｗｔ１の産物に基づく癌抗原
US20040097703A1 (en) * 2001-03-22 2004-05-20 Haruo Sugiyama Wt1 modified peptide
CA2448109A1 (en) * 2001-05-25 2002-12-05 Thomas Jefferson University Alternative splice forms of proteins as basis for multiple therapeutic modalities
WO2004024175A1 (ja) * 2002-09-12 2004-03-25 Haruo Sugiyama 癌抗原ペプチド製剤
CN100513563C (zh) 2003-11-05 2009-07-15 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
US7622119B2 (en) * 2004-03-31 2009-11-24 International Institute Of Cancer Immunology, Inc. Cancer antigen peptides derived from WT1
AU2006209951B2 (en) * 2005-02-04 2011-04-14 Survac Aps Survivin peptide vaccine
JP4394724B2 (ja) * 2005-11-30 2010-01-06 株式会社癌免疫研究所 新規ペプチド化合物
EP1988163B1 (en) 2006-02-22 2012-06-27 International Institute of Cancer Immunology, Inc. Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same
US8067533B2 (en) * 2006-02-23 2011-11-29 Fibrex Medical Research & Development Gmbh Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
EP2980219B1 (en) * 2006-12-28 2018-11-14 International Institute of Cancer Immunology, Inc. Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
DK2119778T3 (en) 2007-02-27 2016-01-25 Int Inst Cancer Immunology Inc A process for the activation of the helper T cell, and composition for use in this process
EP2570431A3 (en) * 2007-08-30 2013-05-01 CureDM Group Holdings, LLC Compositions and methods of using proislet peptides and analogs thereof
KR20140009168A (ko) 2010-10-05 2014-01-22 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 헬퍼 ｔ 세포의 활성화 방법
EP2646459B1 (en) 2010-12-02 2020-01-08 Bionor Immuno AS Peptide scaffold design
CN103270047A (zh) * 2010-12-23 2013-08-28 因特塞尔奥地利股份公司 Oprf/i剂及其在住院患者和其他患者中的用途
CN103347892B (zh) 2011-01-06 2016-11-02 比奥诺尔免疫有限公司 单体和多聚体免疫原性肽
WO2012105224A1 (ja) * 2011-01-31 2012-08-09 オリンパス株式会社 ワクチン・アジュバント
EP2868325B1 (en) 2012-07-02 2017-11-01 Sumitomo Dainippon Pharma Co., Ltd. Transdermal cancer antigen peptide preparation
MX2015007745A (es) 2012-12-17 2015-12-15 Otsuka Pharma Co Ltd Metodo para activar la celula t auxiliar.
US9663563B2 (en) 2013-03-12 2017-05-30 Sumitomo Dainippon Pharma Co., Ltd. Aqueous liquid composition
CN105308063B (zh) * 2013-03-29 2019-11-08 大日本住友制药株式会社 Wt1抗原肽缀合物疫苗
WO2014157704A1 (ja) 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン
JP2016539922A (ja) 2013-10-17 2016-12-22 ソウル ナショナル ユニバーシティ アールアンドディービー ファウンデーション 細胞透過性αヘリックスペプチド多量体、これの製造方法およびその用途
CN106687129B (zh) * 2014-09-27 2021-07-20 大日本住友制药株式会社 注射用药物组合物
JP6671141B2 (ja) * 2014-10-21 2020-03-25 大日本住友製薬株式会社 懸濁液剤
EP3299028A4 (en) * 2015-05-20 2019-02-27 Sumitomo Dainippon Pharma Co., Ltd. COMBINATION OF ANTIGEN WT1 PEPTIDE AND IMMUNOMODULATOR
CA2992419C (en) 2015-07-14 2023-08-15 Yeda Research And Development Co. Ltd. Peptide combinations for use in the diagnosis of schizophrenia
CN111741972A (zh) * 2017-12-27 2020-10-02 大日本住友制药株式会社 Wt1衍生肽的缀合物和包含其的组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0841068B1 (en) * 1995-06-01 2006-07-12 Kishimoto, Tadamitsu Leukemic cell growth inhibitor containing antisense oligonucleotide derivative against wilms' tumor gene (wt1)
JP3060287B2 (ja) 1995-10-09 2000-07-10 参天製薬株式会社 アパファントを主薬とする水性点眼剤
JP4422903B2 (ja) 1998-07-31 2010-03-03 株式会社癌免疫研究所 癌抑制遺伝子ｗｔ１の産物に基づく癌抗原
AU6407899A (en) * 1998-09-30 2000-04-17 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
JPWO2002047474A1 (ja) 2000-12-13 2004-04-15 住友製薬株式会社 Ｈｌａ−ａ２４発現トランスジェニック動物及びその利用
US20040097703A1 (en) 2001-03-22 2004-05-20 Haruo Sugiyama Wt1 modified peptide
WO2003028757A1 (fr) * 2001-09-28 2003-04-10 Haruo Sugiyama Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes
JPWO2003028758A1 (ja) * 2001-09-28 2005-01-13 治夫 杉山 抗原特異的ｔ細胞の誘導方法
JP4365784B2 (ja) * 2002-06-12 2009-11-18 株式会社癌免疫研究所 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
CN100513563C (zh) 2003-11-05 2009-07-15 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
US7622119B2 (en) 2004-03-31 2009-11-24 International Institute Of Cancer Immunology, Inc. Cancer antigen peptides derived from WT1

Also Published As

Publication number Publication date
EP1584627B1 (en) 2009-10-07
KR20120054644A (ko) 2012-05-30
EP1584627A4 (en) 2006-03-15
CN1756763B (zh) 2010-05-26
JP4498274B2 (ja) 2010-07-07
EP2154145A2 (en) 2010-02-17
US8242084B2 (en) 2012-08-14
AU2004204031A1 (en) 2004-07-29
WO2004063217A1 (ja) 2004-07-29
JPWO2004063217A1 (ja) 2006-06-01
KR101399678B1 (ko) 2014-05-27
BRPI0406800B1 (pt) 2020-08-11
BRPI0406800A8 (pt) 2016-11-01
US20060217297A1 (en) 2006-09-28
ATE444969T1 (de) 2009-10-15
EP2154145B1 (en) 2013-04-24
EP1584627A1 (en) 2005-10-12
US20100292164A1 (en) 2010-11-18
CA2513701C (en) 2013-06-18
JP4926231B2 (ja) 2012-05-09
CA2513701A1 (en) 2004-07-29
CN101851275A (zh) 2010-10-06
HK1141539A1 (en) 2010-11-12
KR20050098863A (ko) 2005-10-12
BRPI0406800B8 (pt) 2021-05-25
ES2332590T3 (es) 2010-02-09
JP2010047603A (ja) 2010-03-04
EP2154145A3 (en) 2010-05-19
CN1756763A (zh) 2006-04-05
AU2004204031B2 (en) 2010-03-04
HK1081975A1 (en) 2006-05-26
DE602004023476D1 (de) 2009-11-19

Similar Documents

Publication Publication Date Title
HK1141539A1 (en) Dimerized peptide
CY1119106T1 (el) Αντισωματα εναντι masp-2
RS51180B (sr) Interleukin-10 antitela
WO2003102157A3 (en) Synthetic antibody phage libraries
WO2007064919A3 (en) Binding polypeptides with restricted diversity sequences
CY1117031T1 (el) Μονοκλωνικα αντισωματα εναντι claudin-18 στην αγωγη εναντι καρκινου
DK1625209T3 (da) Kimære immunoglobulin-monomer-dimer-hybrider
CY1113850T1 (el) Νεα παραγωγα ινσουλινης
ATE542137T1 (de) Immunocytokine mit modulierter selektivität
DK1718677T3 (da) Monovalente antistoffragmenter egnede som terapeutiske midler
DE602006010072D1 (de) Il-1 bindende antikörper und fragmente davon
ATE545703T1 (de) Multivalentes zielbindendes protein
CY1112993T1 (el) Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
DE60238993D1 (de) Hybrid und tandemproteine von neisseria sp
DE602005008996D1 (de) Radiofluorierte peptide
RS54046B1 (en) ANTI-MIOSTATIN ANTITELA
WO2005012531A3 (en) Antibody cdr polypeptide sequences with restricted diversity
ATE497975T1 (de) Il-21-varianten
HK1071898A1 (en) Recombinant antibodies, and compositions and methods for making and using the same
IL172729A0 (en) Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins
ATE543833T1 (de) Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen
DE502004011395D1 (de) Protein-bindende doxorubicin-peptid-derivate
EP2305710A3 (en) Synthetic antibody phage libraries
ATE467421T1 (de) Cytokine und cytokinrezeptoren mit reduzierter immunogenität
ATE470678T1 (de) Emitter-bindende peptide, die eine veränderung der spektralen emissionseigenschaften des emitters bewirken

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: CHUGAI SEIYAKU KABUSHIKI KAISHA (CHUGAI PHARMACEUT

B25A Requested transfer of rights approved

Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/08/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/01/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25D Requested change of name of applicant approved

Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) ; SUMITOMO PHARMA CO., LTD. (JP)

B25G Requested change of headquarter approved

Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) ; SUMITOMO PHARMA CO., LTD. (JP)